EGFR+ Lung Cancer

Elevated Dose of Osimertinib Induced Clinical Activity in EGFR Exon 20-Mutant NSCLC

June 02, 2020

A daily dose of osimertinib at 160 mg was well-tolerated with clinical activity observed in patients with EGFR exon 20-mutant non–small cell lung cancer, according to results from the phase 2 ECOG-ACRIN 5162 trial.

High-Dose Osimertinib Shows Limited Benefit in EGFR+ NSCLC With CNS Involvement

June 02, 2020

Treatment with high-dose osimertinib showed positive survival and central nervous system progressive disease control in a real-world cohort of patients with EGFR-mutant non–small cell lung cancer, but these results were not statistically significant.

FDA Approves Frontline Ramucirumab/Erlotinib for EGFR+ mNSCLC

May 30, 2020

The FDA has approved ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non–small cell lung cancer harboring EGFR exon 19 deletions or exon 21 mutations.

Adjuvant Osimertinib Leads to Significant Boost in DFS in Early-Stage EGFR+ NSCLC

May 28, 2020

"Adjuvant osimertinib is the first targeted agent in a global randomized trial to show a statistically significant and clinically meaningful improvement in disease-free survival in patients with stage IB/II/IIIA EGFR mutation–positive non–small cell lung cancer."

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung Cancer

May 06, 2020

Suresh S. Ramalingam, MD, discusses the phase III FLAURA trial.

Almonertinib Induces Response in EGFR T790M-Positive NSCLC With CNS Metastases

May 05, 2020

The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile.

Patients With EGFR Exon 20-Mutated NSCLC Demonstrate Response With Poziotinib

April 28, 2020

Interim findings of the ongoing phase II ZENITH20 trial demonstrated that poziotinib induced a 68.7% disease control rate when used as treatment of patients with pretreated non–small cell lung cancer harboring an EGFR exon 20 insertion.

Aggarwal Reviews the Latest Data Related to Systemic Therapy in Stage III NSCLC

April 19, 2020

In a Targeted Oncology case-based peer perspectives live discussion, Charu Aggarwal, MD, MPH, discussed systemic treatment options for stage III non–small cell lung cancer, based on a real case of a 63-year-old male patient.

Pembrolizumab Deemed Active Treatment for Brain Metastasis in NSCLC

April 15, 2020

Brain metastasis responses were elicited from treatment with pembrolizumab in patients with non–small cell lung cancer, in a PD-L1–positive cohort of a phase II clinical trial conducted by researchers at Yale Cancer Center. According to a YCC press release, pembrolizumab prolonged overall survival with limited toxicity in these patients.

FDA Clears IND for Novel Immunotherapy in Solid Tumors

April 15, 2020

The FDA has provided clearance to an Investigational New Drug application for GT103 for the treatment of solid tumors. A phase I clinical trial will be initiated to evaluate this novel targeted immunotherapy in patients with refractory non–small cell lung cancer, announced Grid Therapeutics, LLC.